{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Patel SA"],"funding":["National Cancer Institute","NCI NIH HHS"],"pagination":["10-18"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9023050"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["63(1)"],"pubmed_abstract":["Acute myeloid leukemia (AML) is an aggressive malignancy of stem cell origin that contributes to significant morbidity and mortality. The long-term prognosis remains dismal given the high likelihood for primary refractory or relapsed disease. An essential component of relapse is resurgence from the bone marrow. To date, the murine hematopoietic stem cell (HSC) niche has been clearly defined, but the human HSC niche is less well understood. The design of niche-based targeted therapies for AML must account for which cellular subsets compete for stem cell occupancy within respective bone marrow microenvironments. In this review, we highlight the principles of stem cell niche biology and discuss translational insights into the AML microenvironment as of 2021. Optimization of competition for ni"],"journal":["Leukemia & lymphoma"],"pubmed_title":["Niche-directed therapy in acute myeloid leukemia: optimization of stem cell competition for niche occupancy."],"pmcid":["PMC9023050"],"funding_grant_id":["K08 CA248940","1K08CA248940-01"],"pubmed_authors":["Lloyd MR","Fan AC","Dalela D","Patel SA","Zhang TY"],"additional_accession":[]},"is_claimable":false,"name":"Niche-directed therapy in acute myeloid leukemia: optimization of stem cell competition for niche occupancy.","description":"Acute myeloid leukemia (AML) is an aggressive malignancy of stem cell origin that contributes to significant morbidity and mortality. The long-term prognosis remains dismal given the high likelihood for primary refractory or relapsed disease. An essential component of relapse is resurgence from the bone marrow. To date, the murine hematopoietic stem cell (HSC) niche has been clearly defined, but the human HSC niche is less well understood. The design of niche-based targeted therapies for AML must account for which cellular subsets compete for stem cell occupancy within respective bone marrow microenvironments. In this review, we highlight the principles of stem cell niche biology and discuss translational insights into the AML microenvironment as of 2021. Optimization of competition for ni","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-22T05:51:23.704Z","creation":"2025-04-05T21:27:16.58Z"},"accession":"S-EPMC9023050","cross_references":{"pubmed":["34407733"],"doi":["10.1080/10428194.2021.1966779"]}}